GeneDx (WGS) Insider Eli Casdin Buys 4,248 Shares
Eli Casdin recently purchased 4,248 shares of GeneDx Holdings Corp. (WGS).
Reviewed by automated data checks against the source filing. How we make and check alerts
Eli Casdin bought 4,248 shares of GeneDx Holdings Corp. ($WGS) on June 18, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $WGS is up 16.4% after 1 week, up 2.8% after 1 month and up 7.8% to date (from the $59.01 close on Jun 18, 2026).
WGS
GeneDx Holdings Corp.
Key Points
- Eli Casdin bought 4,248 shares of GeneDx Holdings Corp. (WGS) on June 18, 2026, as an unplanned transaction.
- Shares of GeneDx traded around $55.42 on Wednesday, with a market cap of $1.65 billion and a forward P/E of 45.0.
- Analysts from Piper Sandler maintained a 'buy' rating on June 23, 2026, with a price target of $63.00.
Get $WGS trade alerts by text
We text you when insiders, Congress or big funds trade $WGS. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated GeneDx Holdings Corp. alert may contain errors. Disclosures
Eli Casdin has acquired 4,248 shares of GeneDx Holdings Corp. (NASDAQGS: WGS) on June 18, 2026. This purchase was not part of a pre-planned trading program. The transaction did not have a reported value or price per share.
Insider Buying and Selling at GeneDx Holdings Corp.
On June 18, 2026, several insiders at GeneDx Holdings Corp. were active in the market. Eli Casdin, along with Joshua Ruch and Thomas Fuchs, each bought 4,248 shares. On the same day, insiders like Jason Ryan and Keith Meister sold 3,576 shares each. These transactions were not planned under Rule 10b5-1.
GeneDx Holdings Corp. Stock Down 42.6%
Shares of GeneDx Holdings Corp. (NASDAQGS: WGS) traded around $55.42 on Wednesday. The company, with a market cap of approximately $1.65 billion, has a forward P/E ratio of 45.0 and a beta of 1.971. Over the past year, the stock has seen a low of $32.21 and a high of $170.87. Its 50-day moving average stands at $54.79, while the 200-day moving average is $99.42. GeneDx maintains a current ratio of 3.09 and a quick ratio of 2.83, with a debt-to-equity ratio of 66.19.
Analysts Set New Price Targets
On June 23, 2026, Piper Sandler maintained its 'buy' rating on GeneDx Holdings Corp., setting a price target of $63.00. Other firms like Canaccord Genuity and Guggenheim also have 'buy' ratings, with targets ranging from $70.00 to $100.00. The consensus among nine analysts is a 'strong buy,' with a mean target price of $77.00.
About GeneDx Holdings Corp.
GeneDx Holdings Corp. is a genomics company based in Stamford, Connecticut, specializing in genetic testing services. Founded in 2000, it focuses on diagnostics for pediatric and rare diseases, utilizing whole exome and genome sequencing. The company also develops an AI-based platform for analyzing next-generation sequencing data. Kevin Feeley serves as the CEO, leading a team of approximately 1,300 employees.
Bottom Line
Eli Casdin's recent purchase of GeneDx shares highlights ongoing insider interest in the company. With a strong market presence in the genomics sector and a forward-looking P/E ratio, GeneDx remains a company to watch. Investors should note that insider transactions are reported after they occur and may not reflect current holdings.
Related Filing Alerts
Source: Eli Casdin's Form 4 filing on $WGS (Jun 18, 2026). Find the original filing: WGS Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts